Monash tests show strong cardioprotective qualities for Algorae drug candidate

The Market Herald11-29 07:43

Algorae Pharmaceuticals Ltd (ASX:1AI) has found that its drug candidate AI-168 has strong cardioprotective qualities, performing better than existing first line FDA-approved beta blockers in three ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2487327996?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-29 07:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2487327996","market":"us","top_or_hot":-1,"title":"Monash tests show strong cardioprotective qualities for Algorae drug candidate","media":"The Market Herald","content":"<div>\n<p>Algorae Pharmaceuticals Ltd (ASX:1AI) has found that its drug candidate AI-168 has strong cardioprotective qualities, performing better than existing first line FDA-approved beta blockers in three ...</p>\n\n<a href=\"https://themarketonline.com.au/monash-tests-show-strong-cardioprotective-qualities-for-algorae-drug-candidate-2024-11-29/\">Source Link</a>\n\n</div>\n","source":"markerherald_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monash tests show strong cardioprotective qualities for Algorae drug candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonash tests show strong cardioprotective qualities for Algorae drug candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-29 07:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://themarketonline.com.au/monash-tests-show-strong-cardioprotective-qualities-for-algorae-drug-candidate-2024-11-29/><strong>The Market Herald</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Algorae Pharmaceuticals Ltd (ASX:1AI) has found that its drug candidate AI-168 has strong cardioprotective qualities, performing better than existing first line FDA-approved beta blockers in three ...</p>\n\n<a href=\"https://themarketonline.com.au/monash-tests-show-strong-cardioprotective-qualities-for-algorae-drug-candidate-2024-11-29/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PCT","symbol_name":"PureCycle Technologies Inc.","start_time":0,"source_url":"https://themarketonline.com.au/monash-tests-show-strong-cardioprotective-qualities-for-algorae-drug-candidate-2024-11-29/","article_id":"2487327996","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2487327996","pubTimestamp":1732837380,"sourceInfo":{"source_id":"markerherald_stock","name":"The Market Herald"},"weMediaInfo":null,"summary":"Algorae Pharmaceuticals Ltd  has found that its drug candidate AI-168 has strong cardioprotective qualities, performing better than existing first line FDA-approved beta blockers in three cardiovascular cell lines.These results were based on preclinical studies of AI-168, whose composition was also refined as a result, with Algorae filing an International Patent Cooperation Treaty  application, enabling it to pursue patent protection for the drug candidate in commercially significant jurisdictions.The preclinical tests were undertaken at Monash University Victorian Heart Institute Research Laboratories, and sought to assess the formulation of AI-168 and compare its performance with beta blockers using well-established in vitro models of cardiovascular disease.In terms of intellectual property strategy, Algorae announced the filing of an initial patent application on November 23, with the more recent PCT patent application including data received after that point through the preclinical","collect":0,"end_time":0,"defaultTopTitle":"themarketonline.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"PCT":"PureCycle Technologies Inc.","BK4090":"商品化工","BK7067":"生物科技","1AI.AU":"ALGORAE PHARMACEUTICALS LTD"},"translate_title":"莫纳什测试显示Algorae候选药物具有强大的心脏保护作用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"1AI.AU":1,"PCT":1},"content_text":"Algorae Pharmaceuticals Ltd (ASX:1AI) has found that its drug candidate AI-168 has strong cardioprotective qualities, performing better than existing first line FDA-approved beta blockers in three cardiovascular cell lines.\nThese results were based on preclinical studies of AI-168, whose composition was also refined as a result, with Algorae filing an International Patent Cooperation Treaty (PCT) application, enabling it to pursue patent protection for the drug candidate in commercially significant jurisdictions.\nThe preclinical tests were undertaken at Monash University Victorian Heart Institute Research Laboratories, and sought to assess the formulation of AI-168 and compare its performance with beta blockers using well-established in vitro models of cardiovascular disease.\nAI-168 is itself a combination drug candidate comprised of a cardio selective beta blocker with cannabidiol.\nIn terms of intellectual property strategy, Algorae announced the filing of an initial patent application on November 23, with the more recent PCT patent application including data received after that point through the preclinical work. The latter application is an important one for international patent protection for AI-168.\nAlgorae has been trading at 0.7 cents.\nJoin the discussion: See what HotCopper users are saying about Algorae and be part of the conversations that move the markets.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2487327996"}